Skip to main content

Advertisement

SpringerLink
Log in

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: Based on previous experience, we combined topotecan with paclitaxel (weekly administration) in patients with non-small-cell lung cancer (NSCLC). Our primary objective was to determine the response rate and survival and our secondary objective, the safety of the regimen. Methods: From October 2003, until March 2005, 45 patients all with histologically or cytologically confirmed NSCLC were enrolled. All patients were chemotherapy and radiotherapy naive. Both agents were infused on day 1 of every week once for three consecutive weeks, every 28 days. Three infusions were considered as one course. The treatment plan was to give three courses (nine infusions) and then to evaluate the response. Topotecan (1.75 mg/m2) was infused for 30 min and paclitaxel (70 mg/m2) for 90 min; these doses had been established as the maximum tolerated dose in a previous phase I–II trial. Results: Eighteen/45 (40%) patients responded, 2 (4.4%) complete responses and 16 (35.6%) partial responses. Twenty-one (46.7%) patients had stable disease, and 6 (13.3%) disease progression. The median duration of response was 8 months and median time to tumor progression 9 months. Grade 3 and 4 neutropenia was observed in two patients (in these two patients, the dose of both drugs was reduced by 25% and G-CSF was given), grade 4 thrombocytopenia in one patient and grade 4 anemia in one patient. Conclusion: This novel combination of topotecan–paclitaxel in a weekly administration rendered a 40% response rate, with very low toxicity in stages IIIA, IIIB and IV NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1

Similar content being viewed by others

References

  1. Fosella FV, de Vore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362

    PubMed  Google Scholar 

  2. Georgoulias V, Kouroussis CH Androulakis N et al (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17:914–920

    PubMed  CAS  Google Scholar 

  3. Stathopoulos GP, Veslemes M, Georgatou N et al (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15:1048–1055

    Article  PubMed  CAS  Google Scholar 

  4. Crino L, Scagliotti G, Maragolo M et al (1997) Cisplatin–gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15:297–303

    PubMed  CAS  Google Scholar 

  5. Huizing MT, Giaccone G, van Warmerdam LJC et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15:317–329

    PubMed  CAS  Google Scholar 

  6. Belani CP, Keams CM, Zuhowski EG et al (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combinations paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17:676–684

    PubMed  CAS  Google Scholar 

  7. Iaffaioli RV, Tortoriello A, Facchini G et al (1999) Phase I–II study of gemcitabine and carboplatin in stage IIIB–IV non-small-cell lung cancer. J Clin Oncol 17:921–926

    PubMed  CAS  Google Scholar 

  8. Pectasides D, Aspropotamitis A, Halikia A et al (1999) Combination chemotherapy with carboplatin, docetaxel, gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17:3816–3821

    PubMed  CAS  Google Scholar 

  9. Comella P, Frasci G, Panza N et al (2000) Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18:1451–1457

    PubMed  CAS  Google Scholar 

  10. Depierre A, Chastang CI, Quoix E et al (1994) Vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial. Ann Oncol 5:37–42

    PubMed  CAS  Google Scholar 

  11. Oshita F, Noda K, Nishiwaki Y et al (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 15:304–309

    PubMed  CAS  Google Scholar 

  12. Lorusso V, Carpagnano F, Frasci G et al (2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18:405–411

    PubMed  CAS  Google Scholar 

  13. Dimitroulis J, Stathopoulos GP (2005) Evolution of non-small-cell lung cancer chemotherapy (Review). Oncol Rep 13:923–930

    PubMed  CAS  Google Scholar 

  14. Sargent DJ, Niedzwiecki D, O’Connell MJ et al (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:144–145

    Article  PubMed  CAS  Google Scholar 

  15. Rougier P, van Custem E, Bajetta E et al (1998) Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412

    Article  PubMed  CAS  Google Scholar 

  16. Cunningham D, Pyrhonen S, James RD et al (1998) Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418

    Article  PubMed  CAS  Google Scholar 

  17. Ardizzoni A, Hansen H, Dombernowsky P et al (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090–2096

    PubMed  CAS  Google Scholar 

  18. Markman M (1997) Topotecan: an important new drug in the management of ovarian cancer. Semin Oncol 4(Suppl 5):55–58

    Google Scholar 

  19. Bokkel Huinick WT, Gore M, Carmichael J et al (1997) Topotecan vs paclitaxel for the treatment or recurrent epithelial ovarian cancer. J Clin Oncol 15:2183–2187

    PubMed  Google Scholar 

  20. Stathopoulos GP, Rigatos SK, Christodoulou Ch et al (2004) Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54:259–264

    Article  PubMed  CAS  Google Scholar 

  21. Rowinsky EK (2002) Weekly topotecan: an alternative to topotecan’s standard daily x5 schedule? Oncologist 7:324–328

    Article  PubMed  CAS  Google Scholar 

  22. Greco A, Hainsworth JD (1997) Paclitaxel (1-h infusion) plus carboplatin in the treatment of advanced non-small-cell lung cancer: results of a multicenter phase II trial. Semin Oncol 24:512–514, S12–S17

    Google Scholar 

  23. Bonomi P, Kim KM, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 18:623–631

    PubMed  CAS  Google Scholar 

  24. Kosmidis P, Milonakis N, Fountzilas G et al (1997) Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small-cell lung cancer: a randomized study. Semin Oncol 24:12–30, S12–S33

    Google Scholar 

  25. Akerley W, Glantz M, Choy H et al (1998) Phase I trial of weekly paclitaxel in advanced lung cancer. J Oncol 16:153–157

    CAS  Google Scholar 

  26. Frasci G, Panza N, Comella P et al (1999) Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 10:355

    Article  PubMed  CAS  Google Scholar 

  27. Miller AB, Hoogstraten B, Staqnet M (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  28. Therasse P, Arbuck SG, Eisenhower EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  29. Giaccone G (2004) Twenty-five years of treating advanced NSCLC: what have we achieved? Ann Oncol 15:Siv83

    Article  Google Scholar 

  30. Kouroussis Ch, Androulakis N, Kakolyris St et al (1998) First-line treatment of advanced non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer 83:2083–2090

    Article  PubMed  Google Scholar 

  31. Miller VA, Krug LM, Ng KK et al (2000) Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:1346–1350

    PubMed  CAS  Google Scholar 

  32. Frasci G, Lorousso V, Panza N et al (2000) Gemcitabine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Oncology Department, Errikos Dunant Hospital, Athens, Greece

    G. P. Stathopoulos, J. Stathopoulos & E. Dimou

  2. Thriacion Hospital, Athens, Greece

    C. Katis & D. Karaindros

  3. IKA, Thessaloniki, Greece

    D. Tsavdaridis

  4. 6th Clinic, Sotiria Hospital, Athens, Greece

    J. Dimitroulis

  5. Semitelou 2A, 115 28, Athens, Greece

    G. P. Stathopoulos

Authors
  1. G. P. Stathopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Katis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Tsavdaridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Dimitroulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Karaindros
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Stathopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Dimou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. P. Stathopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stathopoulos, G., Katis, C., Tsavdaridis, D. et al. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. Cancer Chemother Pharmacol 58, 555–560 (2006). https://doi.org/10.1007/s00280-006-0204-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0204-y

Keywords

Search

Navigation